Spain Unveils Comprehensive Drug Law Reform with Dynamic Pricing, Nurse Prescribing, and Strategic Medicine Provisions

Spain's Council of Ministers on July 21 approved the referral to Parliament of a comprehensive Medicines and Medical Devices Bill, representing a sweeping reform of the regulatory framework currently governed by Royal Legislative Decree 1/2015. The legislation pursues three fundamental objectives: guaranteeing equitable access to therapeutic innovation, ensuring the supply of critical medicines, and strengthening the sustainability of the National Health System (NHS) through an independent evaluation model and more competitive pricing mechanisms.

The bill, which will now undergo debate in the Congress of Deputies for final approval, introduces several landmark changes to Spain's pharmaceutical landscape, including a new drug pricing architecture, expanded prescribing authority for healthcare professionals, and mechanisms to safeguard the supply of essential medications.

Strategic Medicines: A Shield Against Shortages

One of the most significant innovations in the regulation is the introduction of the concept of "strategic medicine," defined as a drug essential to the health system whose supply chain is particularly vulnerable. The Spanish Agency for Medicines and Health Products (AEMPS) (搜索)搜索该词条 will be empowered to adopt special economic and regulatory measures to prevent shortages of these critical products.

In the context of public health emergencies, the bill strengthens obligations on pharmaceutical companies, distributors, and pharmacies to report stock levels of these strategic medicines. This provision aims to provide health authorities with real-time visibility into supply vulnerabilities before they escalate into full-blown shortages.

A Three-Pillar Pricing Overhaul

The bill fundamentally reorganizes how drug prices are set in Spain, combining two distinct methods that may never be applied simultaneously to the same medicine. The traditional reference pricing system is maintained as the general rule, grouping medicines with the same active ingredient and administration route to establish a maximum price ceiling that the State is willing to pay.

Alongside this, the legislation creates a dynamic pricing mechanism specifically designed for off-patent medicines, such as generics. Under this system, a drug's price will be automatically reduced as its market presence increases. For instance, when a generic reaches 50% or 70% of total sales within its group, the law will mandate a reduction in its industrial price, making prices "more competitive."

The third pillar establishes a range of reimbursed prices within each homogeneous group. The ministry sets a maximum limit covering the cost of the most efficient options, and all medications below this threshold will be financed. Patients who choose a medication within this limit or the cheapest option pay only their usual co-payment percentage. However, those who prefer a specific brand exceeding the limit must pay the price difference in addition to their co-payment. As the government clarifies, the public system does not assume "overcosts" due to brand preferences, while patients retain freedom of choice.

Prescribing Rights for Nurses and Physiotherapists

Addressing a long-standing demand of the healthcare sector, the bill formally recognizes the right of nurses and physiotherapists to prescribe medications and healthcare products within their scope of practice. These professionals are integrated into the prescribing team alongside doctors, dentists, and podiatrists, each operating within their own competencies.

Within one year of the bill's entry into force, the regulatory framework will be updated to harmonize prescribing practices across all authorized professionals, requiring the development of coordination protocols between doctors, nurses, and physiotherapists.

Conditional Funding and Early Access

The legislation permits certain innovative medicines to be incorporated early into public provision when they address an unmet medical need or when treatment cannot be delayed, even amid uncertainty about their effectiveness or definitive economic impact. During a provisional period, the Ministry of Health will evaluate patient responses to these medications. If a benefit is confirmed, "funding may be consolidated under the agreed conditions." Conversely, if results prove unsatisfactory or the final price ends up lower than the provisional one, the pharmaceutical company must compensate or return the corresponding amounts.

Remote Dispensing for Vulnerable Patients

The bill incorporates alternative dispensing methods to improve access to medication in exceptional health situations, including cases of dependence, disability, or vulnerability where patients face difficulty traveling. In these circumstances, patients will not be required to physically visit the hospital pharmacy service or a community pharmacy, "always under the responsibility of the dispensing center and with guarantees of traceability, conservation, transport, and pharmaceutical care." The government emphasizes this is not remote sale of medicines but rather "a way to bring dispensing closer to the patient" in very specific cases.

'Rational Use' as a Guiding Principle

For the first time, the bill enshrines "rational use" as a guiding principle of pharmaceutical policy, establishing it as a shared responsibility among stakeholders in the sector. The aim is to ensure that every patient receives optimal treatment at the appropriate dose and for the appropriate duration, at the lowest possible cost.

Industry Response and Parliamentary Outlook

The main stakeholders in the sector have welcomed the bill, though some are calling for improvements during the parliamentary process. The Spanish Association of Generic Medicines (搜索)搜索该词条 has noted that the legislation may not fully resolve the structural pressure on generic medicine prices, nor is it fully aligned with the new European pharmaceutical policy.

The bill provides for the outright repeal of Royal Legislative Decree 1/2015 of 24 July, which will entail a substantial transformation of the regulatory framework applicable to the sector. The amendments introduced during the parliamentary process and the body of implementing regulations resulting from final approval will together determine how the new framework operates in practice for companies across the medical supply chain.